{"id":"insulin-degludec-100u-ml","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL2107869","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin degludec is a recombinant human insulin analog engineered with an extended half-life through multi-hexamer formation, allowing once-daily dosing. It binds to the insulin receptor on muscle and adipose tissue to facilitate glucose uptake and storage, and simultaneously inhibits gluconeogenesis and glycogenolysis in the liver. This results in improved glycemic control with a lower risk of hypoglycemia compared to older basal insulins due to its ultra-long duration of action and stable pharmacokinetic profile.","oneSentence":"Insulin degludec is a long-acting basal insulin that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:51.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04760626","phase":"PHASE3","title":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1085},{"nctId":"NCT04075513","phase":"PHASE4","title":"Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-10-09","conditions":"Type 1 Diabetes Mellitus","enrollment":343},{"nctId":"NCT03687827","phase":"PHASE4","title":"A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-10-02","conditions":"Diabetes Mellitus, Type 2","enrollment":498},{"nctId":"NCT01154881","phase":"PHASE1","title":"A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tresiba"],"phase":"marketed","status":"active","brandName":"Insulin degludec, 100U/ml","genericName":"Insulin degludec, 100U/ml","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin degludec is a long-acting basal insulin that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}